Press release
Giant Cell Arteritis (GCA) Market is projected to reach USD 3.62 billion by 2034
Giant Cell Arteritis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71357
Giant Cell Arteritis is a chronic autoimmune vasculitis that primarily affects individuals above 50 years of age. It causes inflammation of medium and large arteries, especially the temporal and cranial vessels. Untreated GCA can lead to irreversible complications including permanent vision loss, stroke, and aortic aneurysm. Early diagnosis and prompt corticosteroid therapy are essential, and biologics have transformed long-term disease management.
Key Market Highlights
• 2024 Market Size: USD 1.87 billion
• 2034 Forecast: USD 3.62 billion
• CAGR (2025-2034): 6.7%
• Largest Therapy Class: Corticosteroids
• Fastest-Growing Segment: Biologics (IL-6 inhibitors)
Epidemiology & Patient Insights
1. Prevalence
• Affects 20-30 per 100,000 individuals aged 50+
• Peak incidence occurs between 70-80 years
• Higher prevalence in Northern Europe and North America
2. Gender Distribution
• Women are affected 2-3 times more often than men.
3. Clinical Burden
Common symptoms include:
• Headache
• Jaw claudication
• Fatigue
• Scalp tenderness
• Sudden visual changes (the most serious complication)
4. Comorbid Conditions
Many GCA patients also experience:
• Polymyalgia rheumatica (PMR)
• Cardiovascular disease
• Aortic inflammation
Market Growth Drivers
1. Increasing Use of Biologic Therapies
IL-6 inhibitors have significantly reduced relapse rates and the long-term steroid burden.
2. Rising Geriatric Population
Aging is the strongest risk factor, boosting global patient pool expansion.
3. Advancements in Diagnostics
Improved use of:
• Temporal artery ultrasound
• MRI & PET scanning
• EULAR diagnostic guidelines
has enabled earlier detection and treatment.
4. Growing Awareness of Vision-Loss Risk
Early steroid initiation dramatically reduces blindness risk, increasing treatment urgency.
5. Improved Treatment Pathways
Long-term management strategies emphasize:
• Corticosteroid tapering
• Biologic steroid-sparing agents
• Aortic imaging to detect complications
Market Restraints
• High cost of biologic therapies
• Long-term steroid side effects (fractures, diabetes, hypertension)
• Underdiagnosis in low-resource settings
• Limited rheumatology specialist access
Market Opportunities
1. Expansion of IL-6 and Next-Generation Biologic Agents
New immunomodulators targeting vasculitic pathways are in clinical development.
2. Adoption of Imaging-Based Diagnosis
Ultrasound-first and PET/MRI pathways reduce diagnostic delays.
3. Long-Acting Injectable Formulations
Better adherence and long-term disease control.
4. Digital & AI-Based Monitoring Tools
AI-enabled symptom tracking and blood marker analysis support relapse prediction.
5. Growth in Primary Care Awareness
More general physicians are trained to identify early GCA symptoms.
Segmentation Overview
By Treatment Type
• Corticosteroids
• IL-6 inhibitors (biologics)
• DMARDs
• Immunosuppressants
• Adjunctive pain & inflammation therapies
By Disease Type
• Cranial GCA
• Large-vessel GCA
• Mixed presentation
By Route of Administration
• Oral
• Subcutaneous
• Intravenous
By End User
• Hospitals
• Rheumatology clinics
• Specialty infusion centers
• Home-care settings
Explore Full Report here: https://exactitudeconsultancy.com/reports/71357/giant-cell-arteritis-market
Regional Insights
North America - Largest Market
High biologic adoption, strong reimbursement, and advanced vasculitis treatment infrastructure.
Europe - Well-Defined Clinical Guidelines
Widespread use of imaging-based diagnosis and steroid-sparing recommendations.
Asia Pacific - Fastest Growing Market
Growing elderly population, improved rheumatology care access, and rising diagnostic capabilities.
Latin America - Moderate Growth
Improving availability of biologics and strengthened vasculitis management.
Middle East & Africa - Developing
Better awareness and expanding specialty rheumatology services.
Competitive Landscape
Key companies active in GCA therapeutics include:
• Roche
• Novartis
• GlaxoSmithKline
• Sanofi
• Amgen
• Bristol Myers Squibb
• Pfizer
• Johnson & Johnson
• Teva Pharmaceuticals
• AstraZeneca
Focus areas: IL-6 pathway inhibition, novel steroids-sparing biologics, and next-generation immunomodulatory agents.
Recent Market Developments
• New IL-6 inhibitor clinical data showing extended remission durations
• PET/MRI imaging becoming more common for large-vessel detection
• Updated international guidelines promoting rapid diagnostic pathways
• Biologic therapy expansion into earlier treatment lines
• Integration of digital symptom-monitoring technologies
Future Outlook (2025-2034)
The Giant Cell Arteritis Market is expected to grow steadily as:
• Biologics reshape long-term disease control
• AI-enabled imaging improves early detection
• Precision immunology strengthens personalized treatment
• Corticosteroid-sparing strategies become mainstream
• Global access to autoimmune disease care expands
By 2034, the market is projected to reach USD 3.62 billion, supported by rising biologic adoption and increasing global geriatric populations.
This report is also available in the following languages : Japanese (巨細胞性動脈炎市場), Korean (거대세포 동맥염 시장), Chinese (巨细胞动脉炎市场), French (marché de l'artérite à cellules géantes), German (Markt für Riesenzellarteriitis), and Italian (Mercato dell'arterite a cellule giganti), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71357
Our More Reports:
Tenosynovial Giant Cell Tumors (TSGCTs) Market
https://exactitudeconsultancy.com/reports/70888/tenosynovial-giant-cell-tumors-tsgcts-market
Giant Magneto Resistance (GMR) Sensors Market
https://exactitudeconsultancy.com/reports/64723/giant-magneto-resistance-gmr-sensors-market
Tenosynovial Giant Cell Tumors (TSGCTs) Market
https://exactitudeconsultancy.com/reports/70888/tenosynovial-giant-cell-tumors-tsgcts-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Giant Cell Arteritis (GCA) Market is projected to reach USD 3.62 billion by 2034 here
News-ID: 4309730 • Views: …
More Releases from Exactitude Consultancy
Niemann-Pick Disease Type C (NPC) Market Projected to reach USD 210-260 million …
Market Overview
The Niemann-Pick Disease Type C (NPC) market is growing steadily due to rising diagnosis rates, expansion of genetic testing, and increasing investment in rare neurodegenerative disorders. NPC is an ultra-rare lysosomal storage disease characterized by lipid accumulation in the brain, liver, spleen, and other tissues, leading to progressive neurological decline.
The global market for NPC treatments and supportive care is estimated at USD 110-140 million in 2024 and is projected…
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% duri …
Market Overview
The Neurofibromatosis Type 1 (NF1) market is undergoing a major transformation fueled by advancements in precision oncology, genetic diagnostics, and targeted therapies. NF1 is a common autosomal dominant disorder characterized by café-au-lait spots, plexiform neurofibromas, cutaneous neurofibromas, optic pathway gliomas, skeletal abnormalities, and increased tumor predisposition.
The global market for NF1-related therapies and associated tumor management was valued at an estimated USD 340-440 million in 2024. As novel targeted treatments…
Mucopolysaccharidosis II (Hunter Syndrome) Market Growing at a CAGR of 5.5%-6.0% …
Market Overview
The Mucopolysaccharidosis II (MPS II), or Hunter Syndrome, market is expanding steadily due to increasing diagnostic capabilities, growing awareness of lysosomal storage disorders, and continued adoption of enzyme replacement therapies. MPS II is a rare X-linked recessive metabolic disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, leading to progressive accumulation of glycosaminoglycans (GAGs) in various organs.
The global MPS II market is estimated at USD 1.40-1.50 billion in 2024…
Morquio Syndrome (MPS IV) Market CAGR of approximately 6%-7% during 2025-2032
Market Overview
The Morquio Syndrome (MPS IV) market is experiencing consistent growth driven by improved disease awareness, expanding access to enzyme replacement therapy (ERT), advancements in genetic diagnostics, and ongoing clinical research into next-generation therapies. Morquio Syndrome, a rare lysosomal storage disorder, leads to impaired degradation of keratan sulfate, resulting in skeletal abnormalities, growth delays, and multi-systemic complications.
The global Morquio Syndrome market is estimated to be around USD 550-600 million in…
More Releases for Giant
Strengthening the team of a foodtech giant
Sbermarket delivers groceries and household goods to your home, from supermarkets such as METRO, Auchan, and Vkusville. Customers can set up their orders through the website or mobile application, and then Sbermarket partners do the rest. The pickers go around the store with a list and select only the freshest products, then the couriers deliver the orders to the customers.
Evrone has been helping Sbermarket improve its digital service, and our…
World Road bike Market 2016 By Top Players - Cannondale, Fuji, Giant, Trek, Gian …
The research report titled Road bike has adopted an analytical approach to evaluate the dynamics of the Road bike market. It provides a detailed analysis comprising an in-depth research on the Road bike market growth drivers, restraints, and potential growth opportunities, with key focus on globe. In a chapter-wise format, the report evaluates the demand and supply trends observed in the Road bike market, complete with relevant statistics and graphical…
Next generation (giant) iPhone stolen
A £200 reward has been offered after a next generation iPhone was stolen from a pavement in central London. This time, Apple can breathe easy – it was a giant iPhone 4 replica constructed by Marius Istratescu, a leading designer who goes by the name 'Decoartist' (http://decoartist.co.uk).
The iPhone was two months in the making (with several failed prototypes before it) as a pavement sign for the iPhone repair company…
Africa’s Giant Crocodiles in 3D
Botswana, Africa – 3D Film Factory has been commissioned for the third time to supply 3D camera systems and professional stereoscopic services to Fosters Brothers Productions in order to complete their 3D wildlife documentary. Once again the crew will venture into the wetlands of Botswana, Africa to track the giant, man-eating crocodiles both above and below water.
“Africa is a place of wonderment for me. It’s great to go…
biggAIR giant outdoor screens now available international
The large biggAIR screens are now available internationally for any public events. The German biggAIR Cube GmbH can dispatch them from it's head office close to Frankfurt to any location worldwide.
After a huge success during the 2010 football worldcup with over 110 public viewing parties all over Germany using the innovative biggAIRcube®, the German biggAIR Cube GmbH now offers it's big screens for all events with large audiences.
Using a patented…
friendlyway unveils giant touch-sensitive advertising kiosk
Digital advertising columns with massive 52-inch touch screen display
Munich, Germany, February 10, 2009 – friendlyway, a specialist in interactive digital signage, presents its giant digital advertising kiosks for the first time ever. In the past, conventional posters and advertising displays were neither backlit nor did they include animation or moving pictures, and they definitely were not interactive. With the 90 x 52 inch screen in the new advertising…
